Abstract: A bioreaction module for biochemical reactions, in particular for cell-free polypeptide biosynthesis, having a housing (1) including a system chamber (12) and a supply chamber (10), wherein the system chamber (12) contains a producing system during the biochemical reaction and the supply chamber (10) contains a supply liquid during the biochemical reaction, and the system chamber (12) and the supply chamber (10) are separated by a semi-permeable membrane (7).
The housing (1) comprises a system chamber element (5) and at least one supply chamber element (3) between which the semi-permeable membrane (7) is mounted in such a manner that the system chamber (12) is defined by the system chamber element (5) and the semi-permeable membrane (7) and the supply chamber (10) is defined by the supply chamber element (3) and the semi-permeable membrane (7).
Type:
Grant
Filed:
July 26, 2001
Date of Patent:
December 30, 2003
Assignee:
Roche Diagnostics GmbH
Inventors:
Hans Schels, Horst Menzler, Ulrike Fischer
Abstract: A polypeptide with the properties of collagenase class I from Clostridium histolyticum (CHC I) and the amino acid sequence SEQ ID NO:2 which is optionally N-terminally extended by one or several amino acids of the sequence SEQ ID NO:3 is advantageously suitable for the isolation of cells from mammalian tissue and human tissue.
Type:
Grant
Filed:
September 9, 1999
Date of Patent:
November 5, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Helmut Burtscher, Dorothee Ambrosius, Friederike Hesse
Abstract: The invention concerns a DNA coding a eukaryotic highly active alkaline phosphatase with a specific activity of more than 3000 U/mg. The invention also concerns a process for the production of a DNA according to the invention, a vector containing the DNA according to the invention and a cell line containing this vector. Furthermore the invention concerns a recombinant highly active alkaline phosphatase with a specific activity of more than 3000 U/mg which is coded by the DNA according to the invention.
Type:
Grant
Filed:
May 5, 1999
Date of Patent:
June 18, 2002
Assignee:
Roche Diagnostics GmbH
Inventors:
Werner Hoelke, Rainer Muller, Helmut Burtscher, Jose Luis Millan
Abstract: Improved methods for obtaining polynucleotides comprising sequences which differ between two populations of DNA or CDNA are provided. Improvements include reduction in the number of amplification cycles, use of a nuclease digestion step prior to amplification, a novel oligonucleotide adapter for the practice of the improved method, and novel methods for selective amplification of the desired unique fragments and selective degradation of fragments containing sequences common to both populations. Fragments of a sample population are amplified using a primer that endows the amplification products with resistance to nuclease degradation. Fragments of a control population are amplified using a primer that targets the amplification products for preferential degradation. Multiple cycles of hybridization, nuclease treatment and amplification are utilized to provide enrichment of fragments unique to the sample population.
Type:
Grant
Filed:
June 21, 1999
Date of Patent:
May 22, 2001
Assignee:
Roche Diagnostics Corporation
Inventors:
Garrett W. Lindemann, Paula A. Schueler
Abstract: The invention concerns rhodamine derivatives of the general formulae
in which Ca-Cd each denote a C atom, and Ca and Cb as well as Cc and Cd are either linked together by a single bond or by a double bond; X1 to X16 denote independently of one another halogen, sulfonic acid, hydrogen or an alkyl residue with 1-20 C atoms in which the alkyl residue can be substituted with one or several halogen or sulfonic acid residues; R1 and R2 are either identical or different and denote either hydrogen, alkyl with 1-20 C atoms, polyoxyhydrocarbyl units, phenyl or phenylalkyl with 1-3 carbon atoms in the alkyl chain in which the alkyl and/or phenyl residues can be substituted by one or several hydroxy, halogen, sulfonic acid, amino, carboxy or alkoxycarbonyl groups where alkoxy can have 1-4 carbon atoms, R1 contains at least one activatable group, R2 and X4 can be optionally linked together via a bridge composed of 0-2 C atoms.
Type:
Grant
Filed:
June 2, 1999
Date of Patent:
February 6, 2001
Assignee:
Roche Diagnostics GmbH
Inventors:
Hans-Peter Josel, Rupert Herrmann, Dieter Heindl, Klaus Muhlegger, Gregor Sagner, Karl Heinz Drexhage, Jorg Frantzeskos, Jutta Arden-Jacob